{"doi":"10.1358/dot.2022.58.2.3369188","title":"An update on dapagliflozin for chronic kidney disease","abstract":null,"journal":"Drugs of Today","year":2022,"id":600146,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":965139,"name":"Michael S. Kelly","orcid":"0000-0002-7898-448X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"An update on dapagliflozin for chronic kidney disease","abstract":"Dapagliflozin is an oral agent for type 2 diabetes mellitus (T2DM) belonging to the sodium/glucose cotransporter 2 inhibitor (SGLT2-I) class of antihyperglycemic medications. In clinical trials, dapagliflozin has also been shown to reduce cardiovascular and major renal events. In the DAPA-CKD trial, dapagliflozin significantly reduced the composite renal outcome in patients with chronic kidney disease (CKD). Dapagliflozin represents a new pharmacologic option for reducing CKD progression in patients with and without diabetes.","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35188141","pmcid":null,"openalex_id":"https://openalex.org/W4213008657","authors":[],"funders":[],"total_grants":0,"fwci":0.1329,"citation_percentile":0.45253582,"influential_citations":0,"citation_trend":[{"year":2023,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://doi.org/10.1358/dot.2022.58.2.3369188","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35188141","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Pancreatic function and diabetes","Pancreatic and Hepatic Oncology Research","Clinical Trials as Topic","Diabetes Mellitus, Type 2","Humans","Renal Insufficiency, Chronic","Sodium-Glucose Transporter 2 Inhibitors","Benzhydryl Compounds","Glucosides"],"mesh_terms":["Sodium-Glucose Transporter 2 Inhibitors","Benzhydryl Compounds","Clinical Trials as Topic","Diabetes Mellitus, Type 2","Glucosides","Humans","Renal Insufficiency, Chronic"],"keywords":["Dapagliflozin","Medicine","Kidney disease","Diabetes mellitus","Internal medicine","Type 2 diabetes","Urology","Type 2 Diabetes Mellitus","Clinical trial","Renal function","Endocrinology","Diabetes","Nephropathy","Chronic Kidney Disease","Renal Disorders","Sodium/glucose Cotransporter 2 (Sglt2) Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T12:20:04.487528Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}